Albireo Pharma Inc (NASDAQ:ALBO) Expected to Earn Q1 2020 Earnings of ($1.61) Per Share

Albireo Pharma Inc (NASDAQ:ALBO) – Equities researchers at Jefferies Financial Group issued their Q1 2020 earnings per share (EPS) estimates for shares of Albireo Pharma in a research report issued to clients and investors on Wednesday, November 6th. Jefferies Financial Group analyst E. Yang forecasts that the biopharmaceutical company will post earnings per share of ($1.61) for the quarter. Jefferies Financial Group also issued estimates for Albireo Pharma’s Q2 2020 earnings at ($1.52) EPS and Q4 2020 earnings at ($0.82) EPS.

A number of other research analysts have also recently commented on ALBO. HC Wainwright reiterated a “buy” rating and issued a $62.00 price target on shares of Albireo Pharma in a research note on Sunday, August 11th. BidaskClub cut Albireo Pharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 1st. Wedbush reiterated a “buy” rating and issued a $69.00 price target on shares of Albireo Pharma in a research note on Wednesday. Zacks Investment Research lowered Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 9th. Finally, Cowen reaffirmed a “buy” rating and set a $39.00 target price on shares of Albireo Pharma in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $49.00.

Shares of NASDAQ ALBO opened at $18.94 on Friday. Albireo Pharma has a 1-year low of $16.13 and a 1-year high of $38.69. The firm has a market cap of $257.26 million, a P/E ratio of -4.81 and a beta of 1.47. The business’s 50 day moving average is $19.22 and its 200-day moving average is $27.04.

Albireo Pharma (NASDAQ:ALBO) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.55) by ($0.18). The firm had revenue of $1.39 million for the quarter, compared to the consensus estimate of $1.38 million. Albireo Pharma had a negative return on equity of 51.74% and a negative net margin of 2,403.88%.

Large investors have recently made changes to their positions in the stock. Hartwell J M Limited Partnership raised its position in Albireo Pharma by 8.8% during the 2nd quarter. Hartwell J M Limited Partnership now owns 15,500 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 1,250 shares during the last quarter. Allianz Asset Management GmbH raised its position in Albireo Pharma by 8.0% during the 2nd quarter. Allianz Asset Management GmbH now owns 39,356 shares of the biopharmaceutical company’s stock worth $1,269,000 after purchasing an additional 2,908 shares during the last quarter. Wells Fargo & Company MN raised its position in Albireo Pharma by 40.0% during the 2nd quarter. Wells Fargo & Company MN now owns 18,160 shares of the biopharmaceutical company’s stock worth $585,000 after purchasing an additional 5,192 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Albireo Pharma by 15.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 23,576 shares of the biopharmaceutical company’s stock worth $761,000 after purchasing an additional 3,136 shares during the last quarter. Finally, Marshall Wace North America L.P. raised its position in shares of Albireo Pharma by 57.4% in the 2nd quarter. Marshall Wace North America L.P. now owns 39,888 shares of the biopharmaceutical company’s stock worth $1,286,000 after acquiring an additional 14,544 shares in the last quarter. 73.21% of the stock is owned by institutional investors and hedge funds.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Story: 52-Week High/Low

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.